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Abstract
Background: The objective of this study was to evaluate the safety of twice daily, intra-vaginal use
of 0.5% PRO 2000 Gel for fourteen days in HIV un-infected women at lower as well as higher risk
for HIV acquisition, in Pune, India.
Methods: Forty-two eligible volunteers (30 low-risk and 12 high-risk) were given 0.5% PRO 2000
Gel for intra-vaginal application twice daily for 14 consecutive days.
Results: Twenty-four participants (57%, 95% CI 41%–72%) experienced at least one adverse event
(AE) judged to be possibly related to the product use. There were 17 (40%, 95% CI 26%–57%) mild
AEs and 7 (17%, 95% CI 7%–31%) moderate AEs. There were no serious adverse events and no
AEs judged probably or definitely related to product use. Genitourinary discomfort was reported
by 2/30 (6.67%) participants in the low-risk cohort as compared to 4/12 (33.3%) women in the high-
risk cohort (p = 0.03). Intermenstrual bleeding was reported in 2/30 (6.7%, 95% CI 1.0–22.1)
women from the low risk cohort and 3/12 (25%, 95% CI 5.5–57.2) women from the high-risk
cohort. One participant showed mild elevation of blood gamma glutamyl transferase and two
showed mild elevations in total bilirubin. None of the participants showed detectable PRO 2000 in
their blood after 14 days of product use.
Conclusion: 0.5% PRO 2000 Gel appeared to be safe when used twice-daily by sexually active
HIV-uninfected women from Pune, India. Although genitourinary discomfort and metrorrhagia
were more common in the high-risk cohort, ongoing Phase II/IIb trial would provide data for
generalization of this finding.
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Introduction
Vaginal microbicides are products designed to prevent
sexual transmission of HIV and other sexually transmitted
pathogens[1]. They may help women in situations where
negotiation of male condom use is not possible. PRO
2000 Gel is an investigational vaginal microbicide based
on a synthetic naphthalene sulphonate polymer that has
been shown to be active against HIV, herpes simplex virus
type 2 (HSV-2) and other pathogens causing sexually
transmitted infections (STI) in vitro [2-5]. The vaginal gel
formulation demonstrated protection in animal models
for HIV, HSV-2 and Neisseria gonorrhoeae transmission
[6-8] at strengths as low as 0.5%.
Phase I clinical trials to assess the safety, tolerance and
acceptability of PRO 2000 Gel among women in the
reproductive-age group have been conducted in Europe,
the United States (U.S.) and Africa[9,10]. In addition, tri-
als to assess the safety and acceptability of repeated penile
exposure to PRO 2000 Gel for 7 consecutive days among
HIV un-infected and infected men have been conducted
in the U.S.[11]. None of the previous studies were con-
ducted in Asia. The International Working Group for
Microbicides recommends evaluation of candidate vagi-
nal microbicides for safety, tolerance and acceptability in
populations with different characteristics[12]. The objec-
tive of this study was to evaluate the safety and acceptabil-
ity of 0.5% PRO 2000 Gel among sexually active, HIV un-
infected, low-risk and high-risk women from Pune, India
and to assess if transient findings of cervico-vaginal dis-
ruption reported in pig-tailed macaques treated for 4 days
with PRO 2000 Gel (2% and 4% strengths) [13] were pre-
dictive of human toxicity.
Materials and methods
This collaborative study between National AIDS Research
Institute (NARI), Pune, India and Johns Hopkins Univer-
sity School of Medicine, Baltimore, USA was funded by
the HIV Prevention Trials Network (HPTN). The Ethics
Committee of NARI, the Drug Controller General of India
and the Western Institutional Review Board of Johns Hop-
kins University approved the study protocol. The protocol
was also submitted to the United States Food and Drug
Administration. The study was conducted at our clinic
located in Hirabai Cowasji Jehangir Medical Research
Institute, Jehangir Hospital and Medical Center, Pune,
India.
The study was conducted between July 2003 and March
2004 and HIV uninfected sexually active, low-risk as well
as high risk women were screened for possible enroll-
ment. Women were classified as high-risk if they or their
male partner had a documented Sexually Transmitted
Infection (STI) within three months of screening. Women
between 18 and 45 years of age, HIV-negative by licensed
EIA, having a regular menstrual cycle with a minimum of
21 days between menses, not having any Grade III or
higher hematological, liver and renal abnormality, having
a normal Pap smear at screening, or within the 3 months
prior to screening and those having a single male sexual
partner were enrolled in the study. Women who were
pregnant, lactating or using any intra-uterine contracep-
tive device were not eligible to participate in the study.
The National Institute of Allergy and Infectious Diseases
Table for the Grading of Adult Adverse Experiences (AE)
was used to characterize the severity of Adverse Events
occurring in the study.
Clinical, laboratory procedures and end points
All women provided written informed consent prior to
study participation. Women were screened for their eligi-
bility to participate in the study and if eligible, were
enrolled within 30 days of screening. At screening visits,
demographic data were collected using structured ques-
tionnaires, pelvic examinations were completed and
blood samples collected for HIV testing, Rapid plasma
reagin (RPR) with confirmation by Treponema pallidum
haemagglutination (TPHA), complete blood count, bio-
chemistry and coagulation testing. Participants were
requested to bring their male partners to provide consent
for study participation and HIV testing. Female and male
participants diagnosed with any STI were given treatment
as per the 2001 World Health Organization (WHO)
guidelines for the management of sexually transmitted
infections[14]. Male partners were informed to report to
the study clinic if they had any genital symptom due to
product exposure.
Women were requested to return for an enrollment visit
within two to seven days after menstruation, if the results
of all screening tests were within normal limits. Colpos-
copy was performed at the enrollment visit (considered
study day 0) and at scheduled follow up visits at day 2 and
day 14 (after completing 14 days' of product use). Addi-
tional colposcopic evaluation was done if any clinically
detectable abnormality was seen on naked eye examina-
tion at day 7 or during any unscheduled visit requiring
pelvic examination. The colposcopic evaluation was per-
formed according to the CONRAD/WHO Manual for the
Standardization of Colposcopy for the Evaluation of Vag-
inal Products, Update 2000[15]. The study staff com-
pleted a structured questionnaire whenever an inter-
menstrual bleeding (IMB) episode was observed clinically
or reported by the study participants. The study endpoints
were macroscopic evidence of cervico-vaginal ulceration,
abrasion, severe erythema or edema as determined by
speculum-assisted colposcopic examination or comple-
tion of product use twice-daily for 14 days.AIDS Research and Therapy 2006, 3:4 http://www.aidsrestherapy.com/content/3/1/4
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Participants who were eligible for enrollment based on
pelvic examination, laboratory reports and colposcopy
were given the product kits containing single dose tubes of
0.5% PRO 2000 Gel and an equal number of calibrated
polyethylene vaginal applicators. They were asked to
apply a 2 gm dose of the product intra-vaginally twice
daily (preferably morning and bedtime) for two days
before returning for a follow up clinical and colposcopic
examination on day 2. Product use was continued for
another 5 days and a clinical examination was performed
on day 7. Product use was continued for 7 more days and
the final clinical examination and colposcopy were per-
formed on day 14.
During pelvic examination, specimens were collected for
Pap smear (only at screening), for vaginal pH test using
colorpHast® Indicator strip (0–6) from the vaginal wall,
for wet mount to assess for the presence of trichomonia-
sis, candidiasis or bacterial vaginosis from anterior and
lateral fornix, dried smear from the lateral vaginal wall for
Nugent's scoring[16] and urine examination by polymer-
ase chain reaction (PCR) for gonorrhoea and chlamydia
(only at screening and if indicated at other visits).
Criteria for discontinuation from the product use were
clinical diagnosis of any associated significant side effect,
non-adherence to study protocol or unwillingness of the
participant to continue further product use. Statistical
analysis was performed using the SAS® and StatXact statis-
tical software packages.
Acceptability assessment
Acceptability of the product was assessed after 14 days of
product use on structured questionnaires in case of all
women and through focus group discussions conducted
among women and their male partners.
Results
Seventy women were screened for possible enrollment in
the study, of which 42 were found eligible and were
enrolled in the study. Thirty participants were enrolled in
lower risk and 12 in the higher risk cohort. Baseline
demographics were similar in both low and high-risk
cohorts. Mean age for the enrolled participants was 30.2
years (range 21–42 years). All participants were married
and living with their husbands, and were literate enough
to complete a daily diary; 40 (95%) had studied above 5th
grade. The majority of them had undergone tubal ligation
(33/42, 78.6%), whereas other methods of contraception
Table 1: Summary of self-reported symptoms, Colposcopic findings and Laboratory Adverse Experiences
Self-Reported Adverse Experiences Judged Possibly Related to Study Product
Adverse event Low-risk cohort 
N = 30
 N (Mild, Moderate)
High-risk cohort 
N = 12
 N (Mild, Moderate)
Total N = 42 (%) Outcome
Abdominal pain 6 (5, 1) 3 (1, 3) 9 (21.4%) Resolved
Back pain 3 (3, 0) 1 (1, 0) 4 (9.5%) Resolved
Dyspareunia 1 (1, 0) 0 1 (2.4%) Resolved
Dysuria 1 (1, 0) 0 1 (2.4%) Resolved
Genito-urinary discomfort* 2 (2, 0) 4 (2, 2) 6 (14.3%) Resolved
Colposcopic and Laboratory Adverse Experiences Judged Possibly Related to Study Product
Adverse event Low-risk cohort 
(N = 30)
 N (Mild, Moderate)
High-risk cohort 
(N = 12)
 N (Mild, Moderate)
Total N = 42 (%) Outcome
Candidiasis 2 (0, 2) 0 2 (4.8%) Resolved
Cervical Polyp 2 (2, 0) 0 2 (4.8%) Continuing**
Intermenstrual bleeding (IMB) 2 (2, 0) 2 (2, 0) 4 (9.5%) Resolved
Abrasion
Cervical 0 1 (1, 0) 1 (2.4%) Resolved
Vaginal 1 (1, 0) 0 1 (2.4%) Resolved
Increased GGT 0 1 (1, 0) 1 (2.4%) Resolved at a follow up after 10 days
Hyperbilirubinaemia 2 (2, 0) 0 2 (4.8%) Continuing**
Participants with moderate adverse events were provided symptomatic treatment.
* "Genitor-urinary discomfort" includes "genital burning sensation" & "genital pruritus". ** The adverse events were observed on day 14 at the time 
of study termination and participants did not come for follow up visit.AIDS Research and Therapy 2006, 3:4 http://www.aidsrestherapy.com/content/3/1/4
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being used were oral contraceptive pills (2/42, 4.8%),
male condoms (2/42, 4.8%), and vasectomy in case of
one couple. The remaining 4/42 (9.5%) of couples were
not using any birth control method.
Of the forty-two participants enrolled, forty-one partici-
pants completed the study as planned, and all were con-
sidered adherent to product use (defined as 14
consecutive days of twice daily product use, allowing one
or two days of additional product usage if missed during
the 14 days' of product use). One participant was enrolled
in the study and was dispensed the study product. How-
ever, during the interview with the clinician, the partici-
pant reported irregular vaginal bleeding and hence
terminated after enrollment but before any product was
used. Since she was enrolled in the study, and then termi-
nated, she has been included in the analysis as per the
"intent to treat" analysis.
The median sexual activity reported by the study partici-
pants was 3.3 acts per week over the two-week study
period. Of the 42 enrolled participants, 24 (57%, 95% CI
41%–72%) experienced at least one AE judged to be pos-
sibly related to product use. All AEs were mild or moder-
ate in severity. Table 1 shows the incidences of self-
reported symptoms, pelvic examination/colposcopic
findings and laboratory AEs observed among the study
participants and judged possibly related to the product
use. No serious adverse events were reported and no AEs
were judged to be probably or definitely related to prod-
uct use. No AEs were reported by the participants' male
partners.
None of the colposcopic examinations showed evidence
of ulceration, severe edema, or severe erythema of the vul-
vovaginal epithelium or cervical mucosa. A mild cervico-
vaginal abrasion was observed in two participants at the
scheduled Day-2 pelvic examination. Speculum trauma
was considered a possible cause of each abrasion, and
each resolved within 2–3 days without discontinuation of
PRO 2000 Gel use.
Genito-urinary discomfort which includes "genital burn-
ing sensation" & "genital pruritus" were reported in 2/30
(6.67%, 95% CI 1.0–22.1) women in the low risk cohort
as compared to 4/12 (33.3%, 95% CI 9.4–65.6) women
in the high-risk cohort (P = 0.03). Inter-menstrual bleed-
ing episodes (IMB) were reported in 2/30 (6.7%, 95% CI
1.0–22.1) women from the low risk cohort and 3/12
(25%, 95% CI 5.5–57.2) from the high-risk cohort,
though in one case the event was judged unrelated to
study product use. Of the five participants who were diag-
nosed with IMB, one participant was on oral contraceptive
pills for the past three and a half years and the other four
had undergone tubal ligation.
Of the 42 enrolled participants, 11 (26.2%, 95% CI 14%–
42%) developed asymptomatic candidiasis at follow up
visits and two participants (4.8%, 95% CI 0.6%–16.2%)
developed symptomatic candidiasis on day 7 requiring
temporary stoppage (3 to 5 days) of the product use and
oral medication with fluconazole (150 mg single dose)
and local application of clotrimazole-betamethasone
cream for genital itching.
The mean vaginal pH at enrollment as well as after 14
days of product use was 4.5 and none of the participants
developed an alkaline pH. When the mean microflora
scores of the Lactobacillus morphotypes were evaluated as
per the Nugent's criteria[16], there was reduction in the
normal flora from 30/42 (71%) to 18/42 (46%) partici-
pants after 14 days of product use however, the difference
was not statistically significant. Though not significant the
prevalence of BV decreased from 12% at enrollment to
10% at Day 14 (as per Nugent's criteria). At the Day 14
visit, one participant (2.4%, 95% CI 0.1%–12.6%)
showed mild elevation of blood gamma glutamyl trans-
ferase (Participant's value 40 units/liter, Normal range: 5–
36 U/liter, Grade I of DAIDS Toxicity Table 1.25-2.5 ×
UPN) and two (4.8%, 95% CI 0.6%–16.2%) showed mild
elevation of blood bilirubin levels (Participants' value 1.1
and 1.6 respectively, Normal range: 0.2–1 mg/dl, Grade I
of DAIDS Toxicity table: >1.0 to 1.5 × ULN). The increased
level of blood gamma glutamyl transferase returned to
normal at a follow up visit after 10 days, however, the par-
ticipants with raised bilirubin did not return for a follow
up visit. None of the participants showed clinically signif-
icant changes in hematology parameters, other liver or
renal function tests, or coagulation times. None had
detectable PRO 2000 in plasma after 14 days of the prod-
uct use.
The product was found to be generally acceptable by the
study participants. Almost all the participants who used
the product (40/41, 97.6%, 95% CI 87.1%–100%)
expressed willingness to use the product in future if they
felt at risk of HIV infection.
Discussion
0.5% PRO 2000 Gel was observed to be safe and well tol-
erated in a twice-daily dosage schedule among the low risk
as well as the high-risk women from Pune, India. All AEs
were mild to moderate and transient. PRO 2000 Gel is
one of the five candidate microbicides currently entering
the Phase II/IIb efficacy trials[17] and this study has gen-
erated additional safety data.
The most common symptoms experienced by the study
participants were abdominal discomfort and genito-uri-
nary discomfort. Genitourinary discomfort and IMB were
more common in the high-risk cohort as compared to theAIDS Research and Therapy 2006, 3:4 http://www.aidsrestherapy.com/content/3/1/4
Page 5 of 6
(page number not for citation purposes)
low-risk cohort, and this association needs to be studied
further in the effectiveness trials where the product will be
used by larger number of women for longer duration.
We could not determine the reason for elevated liver func-
tion tests in 3/42 (7.1%) of the study participants since
there was no correlation with the plasma PRO 2000 levels
and it is possible that these changes could have occurred
because of reasons not related to product use. Study dis-
continuation was not warranted due to any of the AEs. In
the absence of a placebo control arm we could not deter-
mine whether the reported AEs were related to PRO 2000
Gel use. It has been previously reported that women who
were intensively monitored and were not using vaginal
products other than tampons were more likely to report
high levels of irritative symptoms[18,19]. In earlier Phase
I studies[9,10], scheduled colposcopic assessments were
not performed after two days of product use as in the
present study. We did not observe any cervico-vaginal epi-
thelial disruption among the study participants after two
days of product use contrary to observations in pig-tailed
macaques after treatment with 2% and 4% PRO 2000
Gel[13].
The IMB episodes experienced by participants in our study
were mild, transient and well tolerated. None of the par-
ticipants reported prior history of IMB episode. IMB was
reported in previous Phase I clinical trials of the same
product[9,10].
Since microbicides will act in a complex environment and
an acidic pH may inactivate HIV and other sexually trans-
mitted pathogens[20,21], the effects of PRO 2000 Gel on
vaginal pH and microflora were also assessed. It was
observed that the acidic pH was maintained in all the par-
ticipants. Although there was a trend toward reduction in
the normal vaginal microflora between enrollment and
14 days of product use, the difference was not statistically
significant. We also observed reduction in incidence of
bacterial vaginosis after 14 days of product use. Efficacy
trials with larger sample size would provide definitive
answers for the effect of PRO 2000 on normal vaginal
flora and bacterial vaginosis. Acceptability of the product
was not affected by the AE experiences and willingness to
use the product in future was high.
To date, there have been relatively few microbicide studies
conducted in India[22], despite the presence of HIV infec-
tion for more than 19 years. Epidemiological studies in
India have reported higher rates of HIV infection among
married, monogamous women [23-25] and microbicides
research has to be accelerated in India through commit-
ment at the policy and program management levels and
by increasing involvement of institutions and non-gov-
ernmental organizations. The necessary infrastructure
such as clinical expertise, laboratory support and data
management facilities needed to conduct microbicide
studies already exist in India and should be utilized.
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